Skip to main content

Advertisement

SpringerLink
Log in

Clinical implications of mismatched repair gene promoter methylation in pancreatic cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

To investigate the relationship between the hypermethylation statuses of the mismatch repair genes (hMLH1 and hMSH2) promoters and explore the correlation between it and the development of pancreatic cancer and the biological behavior of pancreatic cancer. We selected 90 patients who were diagnosed with pancreatic cancer and underwent radical operations in the First Affiliated Hospital of the Dalian Medical University between January 2002 and June 2008. The methylation status of the hMLH1 and hMSH2 promoters was detected by methylation-specific polymerase chain reaction (MSP). Meanwhile, the expression of hMLH1 and hMSH2 protein was detected by Western blot and immunohistochemistry, and its correlation with biological behavior of pancreatic cancer was explored. Of the 90 cases, hMLH1 promoter methylation was detected in 54 (60.0%) patients, while none of the paracancerous tissues indicated methylation. In the study, the hMLH1-methylated tumors lost hMLH1 protein expression, but the non-hMLH1-methylated tumors were not seen to have a loss of hMLH1 protein expression (P < 0.001). On the other hand, there were four cases of hMSH2 promoter methylation. However, no significant difference was found between hMSH2 promoter methylation and non-hMSH2 promoter methylation cases (P > 0.05). After universal analysis, hMLH1 expression was significantly related to tumor differentiation, lymph node metastasis, and tumor location (P < 0.05) while not related to the age, sex, and tumor size (P > 0.05). Our study suggests that the mismatch repair genes play an important role in pancreatic cancer carcinogenesis and progression through epigenetic modification, and it may be regarded as a potential target for the management of pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Dasari A, McCarter M, McManus MC, Russ P, Messersmith WA. Recurrent pancreatic adenocarcinoma after pancreatic resection. Oncology (Williston Park). 2010;24(14):1329–34.

    Google Scholar 

  2. Costello E, Neoptolemos JP. Pancreatic cancer in 2010: new insights for early intervention and detection. Nat Rev Gastroenterol Hepatol. 2011;8(2):71–3.

    Article  PubMed  CAS  Google Scholar 

  3. Chen H, Tu H, Meng ZQ, Chen Z, Wang P, Liu LM. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol. 2010;36(7):657–62.

    Article  PubMed  CAS  Google Scholar 

  4. Dong X, Li Y, Hess KR, Abbruzzese JL, Li D. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist. 2011;16(1):61–70.

    Article  PubMed  CAS  Google Scholar 

  5. Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, Hruban RH, Goldenberg DM. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2010;19(11):2786–94.

    Article  PubMed  CAS  Google Scholar 

  6. Stan SD, Singh SV, Brand RE. Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2010;7(6):347–56.

    PubMed  CAS  Google Scholar 

  7. Morana G, Cancian L, Pozzi Mucelli R, Cugini C. Staging cancer of the pancreas. Cancer Imaging. 2010;10:S137–41.

    Article  PubMed  Google Scholar 

  8. Lahat G, Sever R, Lubezky N, Nachmany I, Gerstenhaber F, Ben-Haim M, Nakache R, Koriansky J, Klausner JM. Pancreatic Cancer: surgery is a feasible therapeutic option for elderly patients. World J Surg Oncol. 2011;9(1):10.

    Article  PubMed  Google Scholar 

  9. Gargiulo S, Torrini M, Ollila S, Nasti S, Pastorino L, Cusano R, Bonelli L, Battistuzzi L, Mastracci L, Bruno W, Savarino V, Sciallero S, Borgonovo G, Nyström M, Bianchi-Scarrà G, Mareni C, Ghiorzo P. Germline MLH1 and MSH2 mutations in italian pancreatic cancer patients with suspected Lynch syndrome. Fam Cancer. 2009;8(4):547–53.

    Article  PubMed  CAS  Google Scholar 

  10. Handra-Luca A, Couvelard A, Degott C, Fléjou JF. Correlation between patterns of DNA mismatch repair hmlh1 and hmsh2 protein expression and progression of dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch. 2004;444(3):235–8.

    Article  PubMed  CAS  Google Scholar 

  11. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery. 2003;134(6):902–8. discussion 909.

    Article  PubMed  Google Scholar 

  12. Tomaszewska R, Okoń K, Stachura J. Expression of the DNA mismatch repair proteins (hMLH1 and hMSH2) in infiltrating pancreatic cancer and its relation to some phenotypic features. Pol J Pathol. 2003;54(1):31–7.

    PubMed  CAS  Google Scholar 

  13. Okada T, Noji S, Goto Y, Iwata T, Fujita T, Okada T, Matsuzaki Y, Kuwana M, Hirakata M, Horii A, Matsuno S, Sunamura M, Kawakami Y. Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis. Int J Cancer. 2005;116(6):925–33.

    Article  PubMed  CAS  Google Scholar 

  14. International Union Against Cancer (UICC). TNM classification of malignant tumors. 5th edition. New York: John Wiley & Sons, Inc., 1997.

  15. Herman GA, Mistry GC, Yi B, Bergman AJ, Wang AQ, Zeng W, Chen L, Snyder K, Ruckle JL, Larson PJ, Davies MJ, Langdon RB, Gottesdiener KM, Wagner JA. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. Br J Clin Pharmacol. 2011;71(3):429–36.

    Article  PubMed  CAS  Google Scholar 

  16. Plevová P, Krepelová A, Papezová M, Sedláková E, Curík R, Foretová L, Navrátilová M, Novotný J, Zapletalová J, Palas J, Nieslanik J, Horácek J, Dvorácková J, Kolár Z. Immunohistochemical detection of the hMLH1 and hMSH2 proteins in hereditary non-polyposis colon cancer and sporadic colon cancer. Neoplasma. 2004;51(4):275–84.

    PubMed  Google Scholar 

  17. Kim JW, Park HM, Choi YK, Chong SY, Oh D, Kim NK. Polymorphisms in genes involved in folate metabolism and plasma DNA methylation in colorectal cancer patients. Oncol Rep. 2011;25(1):167–72.

    PubMed  CAS  Google Scholar 

  18. González-Ramírez I, Ramírez-Amador V, Irigoyen-Camacho ME, Sánchez-Pérez Y, Anaya-Saavedra G, Granados-García M, García-Vázquez F, García-Cuellar CM. hMLH1 promoter methylation is an early event in oral cancer. Oral Oncol. 2011;47(1):22–6.

    Article  PubMed  Google Scholar 

  19. Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Erickson D, Kovacs K, Horvath E, Lloyd RV. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.J Neurooncol. 2011. [Epub ahead of print].

  20. Vasavi M, Kiran V, Ravishankar B, Prabhakar B, Ahuja YR, Hasan Q. Microsatellite instability analysis and its correlation with hMLH1 repair gene hypermethylation status in esophageal pathologies including cancers. Cancer Biomarker. 2010;7(1):1–10.

    CAS  Google Scholar 

  21. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery. 2003;134(6):902–8. discussion 909.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The Second Affiliated Hospital, Dalian Medical University, 116000, Dalian, Liaoning Province, China

    M. Li

  2. Department of General Surgery, The First affiliated Hospital, Dalian Medical University, 116000, Dalian, Liaoning Province, China

    M. Li & Z. W. Zhao

Authors
  1. M. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. W. Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Z. W. Zhao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, M., Zhao, Z.W. Clinical implications of mismatched repair gene promoter methylation in pancreatic cancer. Med Oncol 29, 970–976 (2012). https://doi.org/10.1007/s12032-011-9968-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9968-y

Keywords

Search

Navigation